-
BioPharma Dive – AI / Data2 weeks agoBeam posts positive data on base editing treatment for AATD
Updated data showed the biotech’s approach to the rare lung and liver condition helped restore functional protective proteins in a small study.
-
Endpoints News2 weeks ago
FDA approves Corcept’s Lifyorli for ovarian cancer months early
The FDA approved Corcept Therapeutics’ Lifyorli in combination with nab-paclitaxel for the treatment of three different kinds of cancer in patients who have received up to...
-
AI & Machine Learning in Biotechnology2 weeks agoSTAT+: FDA approves Denali Therapeutics drug for Hunter syndrome
The Food and Drug Administration on Wednesday approved a new medicine from Denali Therapeutics for a condition called Hunter syndrome, a notable decision by the agency...
-
AI & Machine Learning in Biotechnology2 weeks agoSTAT+: A 2023 health AI bet that seems to be paying off
You’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine. Sign up to get it delivered in...
-
GEN – Genetic Engineering & Biotechnology News2 weeks ago
The Three Pillars of Successful AI Deployments
Artificial intelligence and machine learning (AI/ML) are breakthrough tools in biopharmaceutical processing, but they are only as good as the dynamic processes they interact with. You...
-
GEN – Genetic Engineering & Biotechnology News2 weeks ago
Biopharma Benefitting from AI in Manufacturing
Biopharma is embracing artificial intelligence (AI), according to the European industry group, IFMPA, which points to process development and visual inspection as examples of areas where...
-
GEN – Genetic Engineering & Biotechnology News2 weeks ago
Scout-Triggered Proteomics Sharpens HCP Control
Host-cell proteins (HCPs) remain one of bioprocessing’s most stubborn analytical headaches. These residual impurities, shed by production cells during manufacturing, can survive purification and threaten both...
-
Endpoints News2 weeks ago
After tumultuous year, Sarepta plots rebound with early data on RNA therapies
Sarepta Therapeutics reported promise in initial findings from clinical studies of two RNA muscle disease treatments, as the company maps out a future beyond its controversial...
-
Endpoints News2 weeks ago
Beam looks to accelerated approval for AATD base editing after promising update
Beam Therapeutics has provided a much-awaited update on its therapy that uses a form of CRISPR called base editing to precisely fix a single genetic typo...
-
Biotech Industry Intelligence2 weeks ago
Boehringer Ingelheim plans for dealmaking and R&D spending amid US price pressure
Boehringer Ingelheim plans for dealmaking and R&D spending amid US price pressure
